{"cdcTestId":"2013-0416","testcaseName":"Any dose 26 yrs, female, gardasil","vaccineGroup":"HPV","evaluationTestType":"Age: At Recommended","forecastTestType":"Recommended based on interval","assessmentDate":"2022-10-19T00:00:00","patient":{"dob":"1996-10-18T00:00:00","gender":"F"},"evaluation":{"seriesStatus":"Not complete","administeredDoses":[{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"HPV9","cvx":"165","mvx":"","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"2","earliestDate":"2022-11-16T00:00:00","recommendedDate":"2022-11-16T00:00:00","pastDueDate":"2023-02-07T00:00:00"},"doses":[{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"HPV9","cvx":"165","mvx":"","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2013-01-01T00:00:00","dateUpdated":"2018-03-27T08:46:46.76","generalDescription":"This test case describes when a female receives the first dose of the HPV vaccine at age 26 years that a second dose should forecast at an interval of 4 - 8 weeks.","changedInVersion":"3.4","reasonForChange":"V3.4: Earliest Recommended Date was changed from 8 weeks to 4 weeks on Dose 2 per HPV MMWR language. \nV3.0 Updated test came name and date of birth to reflect the age of 26 and to reflect that the second dose of the HPV vaccine should be forecasted."}